A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma

Christopher D. Goodman; Franco DeMonte; Theresa P. Nguyen; Adam S. Garden; Catherine He Wang; Xin A. Wang; Kevin Diao; Anna Lee; Jay Reddy; Amy Moreno; Michael Spiotto; Clifton D. Fuller; David Rosenthal; Renata Ferrarotto; Shaan M. Raza; Shirley Y. Su; Andrew Warner; Ehab Hanna; Jack Phan

doi:10.1002/hed.27887

A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma

Christopher D. Goodman, Franco DeMonte, Theresa P. Nguyen, Adam S. Garden, Catherine He Wang, Xin A. Wang, Kevin Diao, Anna Lee, Jay Reddy, Amy Moreno, Michael Spiotto, Clifton D. Fuller, David Rosenthal, Renata Ferrarotto, Shaan M. Raza, Shirley Y. Su, Andrew Warner, Ehab Hanna, Jack Phan

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Treatment for dural recurrence of olfactory neuroblastoma (ONB) is not standardized. We assess the outcomes of stereotactic body radiotherapy (SBRT) in this population. Methods: ONB patients with dural recurrences treated between 2013 and 2022 on a prospective registry were included. Tumor control, survival, and patient-reported quality of life were analyzed. Results: Fourteen patients with 32 dural lesions were evaluated. Time to dural recurrence was 58.3 months. Thirty lesions (94%) were treated with SBRT to a median dose of 27 Gy in three fractions. Two patients (3 of 32 lesions; 9%) developed in-field radiographic progression, five patients (38%) experienced progression in non-contiguous dura. Two-year local control was 85% (95% CI: 51–96%). There were no >grade 3 acute toxicities and 1 case of late grade 3 brain radionecrosis. Conclusion: In this largest study of SBRT reirradiation for ONB dural recurrence to date, high local control rates with minimal toxicity were attainable.

Original language	English (US)
Journal	Head and Neck
DOIs	https://doi.org/10.1002/hed.27887
State	Accepted/In press - 2024

Keywords

dural recurrence
esthesioneuroblastoma
olfactory neuroblastoma
SBRT
stereotactic radiation

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1002/hed.27887

Cite this

Goodman, C. D., DeMonte, F., Nguyen, T. P., Garden, A. S., Wang, C. H., Wang, X. A., Diao, K., Lee, A., Reddy, J., Moreno, A., Spiotto, M., Fuller, C. D., Rosenthal, D., Ferrarotto, R., Raza, S. M., Su, S. Y., Warner, A., Hanna, E., & Phan, J. (Accepted/In press). A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma. Head and Neck. https://doi.org/10.1002/hed.27887

Goodman, CD, DeMonte, F, Nguyen, TP, Garden, AS, Wang, CH, Wang, XA, Diao, K, Lee, A , Reddy, J , Moreno, A , Spiotto, M , Fuller, CD , Rosenthal, D , Ferrarotto, R , Raza, SM , Su, SY, Warner, A, Hanna, E & Phan, J 2024, 'A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma', Head and Neck. https://doi.org/10.1002/hed.27887

@article{ac1f3c7e69524dfdb09a6a35e04adeaa,

title = "A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma",

abstract = "Background: Treatment for dural recurrence of olfactory neuroblastoma (ONB) is not standardized. We assess the outcomes of stereotactic body radiotherapy (SBRT) in this population. Methods: ONB patients with dural recurrences treated between 2013 and 2022 on a prospective registry were included. Tumor control, survival, and patient-reported quality of life were analyzed. Results: Fourteen patients with 32 dural lesions were evaluated. Time to dural recurrence was 58.3 months. Thirty lesions (94%) were treated with SBRT to a median dose of 27 Gy in three fractions. Two patients (3 of 32 lesions; 9%) developed in-field radiographic progression, five patients (38%) experienced progression in non-contiguous dura. Two-year local control was 85% (95% CI: 51–96%). There were no >grade 3 acute toxicities and 1 case of late grade 3 brain radionecrosis. Conclusion: In this largest study of SBRT reirradiation for ONB dural recurrence to date, high local control rates with minimal toxicity were attainable.",

keywords = "dural recurrence, esthesioneuroblastoma, olfactory neuroblastoma, SBRT, stereotactic radiation",

author = "Goodman, {Christopher D.} and Franco DeMonte and Nguyen, {Theresa P.} and Garden, {Adam S.} and Wang, {Catherine He} and Wang, {Xin A.} and Kevin Diao and Anna Lee and Jay Reddy and Amy Moreno and Michael Spiotto and Fuller, {Clifton D.} and David Rosenthal and Renata Ferrarotto and Raza, {Shaan M.} and Su, {Shirley Y.} and Andrew Warner and Ehab Hanna and Jack Phan",

note = "Publisher Copyright: {\textcopyright} 2024 Wiley Periodicals LLC.",

year = "2024",

doi = "10.1002/hed.27887",

language = "English (US)",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma

AU - Goodman, Christopher D.

AU - DeMonte, Franco

AU - Nguyen, Theresa P.

AU - Garden, Adam S.

AU - Wang, Catherine He

AU - Wang, Xin A.

AU - Diao, Kevin

AU - Lee, Anna

AU - Reddy, Jay

AU - Moreno, Amy

AU - Spiotto, Michael

AU - Fuller, Clifton D.

AU - Rosenthal, David

AU - Ferrarotto, Renata

AU - Raza, Shaan M.

AU - Su, Shirley Y.

AU - Warner, Andrew

AU - Hanna, Ehab

AU - Phan, Jack

PY - 2024

Y1 - 2024

N2 - Background: Treatment for dural recurrence of olfactory neuroblastoma (ONB) is not standardized. We assess the outcomes of stereotactic body radiotherapy (SBRT) in this population. Methods: ONB patients with dural recurrences treated between 2013 and 2022 on a prospective registry were included. Tumor control, survival, and patient-reported quality of life were analyzed. Results: Fourteen patients with 32 dural lesions were evaluated. Time to dural recurrence was 58.3 months. Thirty lesions (94%) were treated with SBRT to a median dose of 27 Gy in three fractions. Two patients (3 of 32 lesions; 9%) developed in-field radiographic progression, five patients (38%) experienced progression in non-contiguous dura. Two-year local control was 85% (95% CI: 51–96%). There were no >grade 3 acute toxicities and 1 case of late grade 3 brain radionecrosis. Conclusion: In this largest study of SBRT reirradiation for ONB dural recurrence to date, high local control rates with minimal toxicity were attainable.

AB - Background: Treatment for dural recurrence of olfactory neuroblastoma (ONB) is not standardized. We assess the outcomes of stereotactic body radiotherapy (SBRT) in this population. Methods: ONB patients with dural recurrences treated between 2013 and 2022 on a prospective registry were included. Tumor control, survival, and patient-reported quality of life were analyzed. Results: Fourteen patients with 32 dural lesions were evaluated. Time to dural recurrence was 58.3 months. Thirty lesions (94%) were treated with SBRT to a median dose of 27 Gy in three fractions. Two patients (3 of 32 lesions; 9%) developed in-field radiographic progression, five patients (38%) experienced progression in non-contiguous dura. Two-year local control was 85% (95% CI: 51–96%). There were no >grade 3 acute toxicities and 1 case of late grade 3 brain radionecrosis. Conclusion: In this largest study of SBRT reirradiation for ONB dural recurrence to date, high local control rates with minimal toxicity were attainable.

KW - dural recurrence

KW - esthesioneuroblastoma

KW - olfactory neuroblastoma

KW - SBRT

KW - stereotactic radiation

UR - http://www.scopus.com/inward/record.url?scp=85199966833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85199966833&partnerID=8YFLogxK

U2 - 10.1002/hed.27887

DO - 10.1002/hed.27887

M3 - Article

C2 - 39073252

AN - SCOPUS:85199966833

SN - 1043-3074

JO - Head and Neck

JF - Head and Neck

ER -

A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this